Skip to search formSkip to main contentSkip to account menu

conatumumab

Known as: Anti-TRAIL Receptor 2 Monoclonal Antibody AMG 655, Immunoglobulin G1, Anti-(Human Tumor Necrosis Factor Receptor Superfamily Member 10b (Death Receptor 5, Trail-R2, CD262 Antigen)), Monoclonal XG1-048 (Arg(Sup 219),Glu(Sup 361),Met(Sup 363))Gamma-1 Heavy Chain (225-215')-Disulphide With Kappa Light Chain (231-231'':234-234'')-Bisdisulphide Dimer 
A fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

AMG 655

Broader (1)

Monoclonal Antibodies
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Implementation of design of experiments (DOE) in the development and validation of a cell-based bioassay for the detection of anti-drug neutralizing antibodies in human serum.
Review
2012
Review
2012
Therapeutic targeting of the TNF superfamily: a promising treatment for advanced endometrial adenocarcinoma.
2012
2012
Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. It is believed to arise from skeletal muscle… 
2012
2012
Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab
Dulanermin (rhApo2L/TRAIL) and conatumumab bind to transmembrane death receptors and trigger the extrinsic cellular apoptotic… 
2012
2012
Conatumumab (CON) plus FOLFIRI (F) or ganitumab (GAN) plus F for second-line treatment of mutant (MT) KRAS metastatic colorectal cancer (mCRC).
534 Background: EGFR inhibitors are not an option for patients (pts) with MT KRAS mCRC; therefore, there is an unmet medical need… 
2011
2011
Characterization of 64Cu-DOTA-Conatumumab: A PET Tracer for In Vivo Imaging of Death Receptor 5
Conatumumab is a fully human monoclonal antibody that binds to and activates human death receptor 5 (DR5; also known as TRAIL… 
2011
2011
Predictive value of Fc gamma receptor IIIa genotype in response to conatumumab in three phase II studies.
3103 Background: Conatumumab (AMG 655) is an investigational, fully human monoclonal agonist IgG1 antibody that selectively binds… 
Review
2011
Review
2011
Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults
Introduction: Advanced malignancies that are refractory to standard chemotherapy have few treatment options. Conatumumab is an… 
2010
2010
Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors.
3102 Background: Preclinical studies show that evasion of death receptor (DR)-mediated apoptosis may depend on intact growth… 
2010
2010
Measurement of conatumumab‐induced apoptotic activity in tumors by fine needle aspirate sampling
Conatumumab is a monoclonal antibody specific for death receptor 5 (DR5) that activates caspases leading to DNA fragmentation and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)